Triple negative breast cancer has a high recurrence rate and poor prognosis and survival outcomes. A 2-drug combo shows promise in reducing tumor growth.
Adherence at 2 years with distribution of essential medicines at no charge: The CLEAN Meds randomized clinical trial plos.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from plos.org Daily Mail and Mail on Sunday newspapers.
RepliCel Launches the Next Stage of a Research Project with the University of British Columbia to Build World-Class Hair Follicle Cell Data Map
ACCESSWIRE
11 May 2021, 20:05 GMT+10
Early identification of unique cell markers is expected to have valuable impact on patents, clinical efficacy, and manufacturing optimization
VANCOUVER, BC / ACCESSWIRE / May 11, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF)(TSXV:RP)(FRA:P6P2) ( RepliCel or the Company ) is pleased to announce it has now signed and launched a new collaborative research project agreement with the University of British Columbia ( UBC ) that enables the second stage of its cell marker research. The project is being co-led by RepliCel s Dr. Kevin McElwee and UBC s Professor Youwen Zhou.
(1)
Early identification of unique cell markers is expected to have valuable impact on patents, clinical efficacy, and manufacturing optimization
VANCOUVER, BC / ACCESSWIRE / May 11, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF)(TSXV:RP)(FRA:P6P2) ( RepliCel or the Company ) is pleased to announce it has now signed and launched a new collaborative research project agreement with the University of British Columbia ( UBC ) that enables the second stage of its cell marker research. The project is being co-led by RepliCel s Dr. Kevin McElwee and UBC s Professor Youwen Zhou.
The project commenced in 2017, is designed to deliver a gene and protein expression map of healthy hair follicle cells expected to be critically important to improving key components of the manufacturing, regulatory, and clinical profile of RepliCel s cell therapy products.